309 related articles for article (PubMed ID: 19927151)
1. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
4. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Sezai A; Soma M; Hata M; Yoshitake I; Unosawa S; Wakui S; Shiono M
Ann Thorac Cardiovasc Surg; 2011; 17(5):487-93. PubMed ID: 21881353
[TBL] [Abstract][Full Text] [Related]
5. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
6. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Taniguchi I; Kawai M; Date T; Yoshida S; Seki S; Taniguchi M; Shimizu M; Mochizuki S
Circ J; 2006 Aug; 70(8):995-1000. PubMed ID: 16864931
[TBL] [Abstract][Full Text] [Related]
7. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
8. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
[TBL] [Abstract][Full Text] [Related]
9. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
[TBL] [Abstract][Full Text] [Related]
10. AT(1) receptor blockers increase insulin-like growth factor-I production by stimulating sensory neurons in spontaneously hypertensive rats.
Harada N; Shimozawa N; Okajima K
Transl Res; 2009 Sep; 154(3):142-52. PubMed ID: 19665690
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II plays an important role in maintaining blood pressure in postmenopausal women receiving hormone replacement therapy.
Sumino H; Ichikawa S; Miya Y; Sakamaki T; Kurabayashi M
Am J Hypertens; 2005 Oct; 18(10):1340-6. PubMed ID: 16202859
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
14. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
[TBL] [Abstract][Full Text] [Related]
15. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
[TBL] [Abstract][Full Text] [Related]
16. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure.
Shibasaki Y; Mori Y; Tsutumi Y; Masaki H; Sakamoto K; Murasawa S; Maruyama K; Moriguchi Y; Tanaka Y; Iwasaka T; Inada M; Matsubara H
Clin Nephrol; 1999 Feb; 51(2):83-91. PubMed ID: 10069643
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure.
Kasama S; Toyama T; Sumino H; Matsumoto N; Sato Y; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2007 Dec; 48(12):1993-2000. PubMed ID: 18006623
[TBL] [Abstract][Full Text] [Related]
18. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
[TBL] [Abstract][Full Text] [Related]
19. Disparate systemic and renal blocking properties of angiotensin II antagonists during exogenous angiotensin II administration: implications for treatment.
Willemsen JM; Rabelink TJ; Boer P; Gaillard CA
J Hum Hypertens; 2004 Dec; 18(12):857-63. PubMed ID: 15361886
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Minatoguchi S; Aoyama T; Kawai N; Iwasa M; Oda M; Kida K; Kojima S; Goto N; Goto M; Sugishita F; Takai K; Tanaka R; Hiei K; Minagawa T; Yamamoto N; Watanabe I; Yasue T; Kobayashi H
Blood Press; 2013 Sep; 22 Suppl 1():29-37. PubMed ID: 23330658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
